Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Advil NDA approval

This article was originally published in The Tan Sheet

Executive Summary

Wyeth Consumer Healthcare receives agency clearance for Advil Cold & Sinus Liquigels May 30. Approved under NDA 21-374, liquigels contain 200 mg ibuprofen, 30 mg pseudoephedrine hydrochloride for "temporary relief" of cold, sinusitis or flu symptoms. Wyeth could be looking to spark new life into its cold and allergy brands, which collectively saw food, drug, mass sales drop 14% to $86 mil. for the 52 weeks ended April 21, according to data from Information Resources, Inc. (Chicago). Advil Cold & Sinus products currently rank ninth in the category, with 52-week sales totaling $40.2 mil. (down 5.2%); the line debuted in 1989. Approval is second this year for Wyeth's Advil franchise; firm will extend its pediatric line with Children's Advil Cold by year end (1"The Tan Sheet" April 29, 2002, p. 5)...

You may also be interested in...

Wyeth Children’s Advil Cold Combination Suspension Extends Pediatric Line

Wyeth Consumer Healthcare's Advil franchise will expand into the pediatric cold category with Children's Advil Cold ibuprofen/pseudoephedrine oral suspension, which is slated to launch later this year

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts